RESUMEN
Tuberculosis (TB) is an infectious disease that causes a great number of deaths in the world (1.5 million people per year). This disease is currently treated by administering high doses of various oral anti-TB drugs for prolonged periods (up to 2 years). While this regimen is normally effective when taken as prescribed, many people with TB experience difficulties in complying with their medication schedule. Furthermore, the oral administration of standard anti-TB drugs causes severe side effects and widespread resistances. Recently, we proposed an original platform for pulmonary TB treatment consisting of mannitol microspheres (Ma MS) containing iron (III) trimesate metal-organic framework (MOF) MIL-100 nanoparticles (NPs). In the present work, we loaded this system with the first-line anti-TB drug isoniazid (INH) and evaluated both the viability and safety of the drug vehicle components, as well as the cell internalization of the formulation in alveolar A549 cells. Results show that INH-loaded MOF (INH@MIL-100) NPs were efficiently microencapsulated in Ma MS, which displayed suitable aerodynamic characteristics for pulmonary administration and non-toxicity. MIL-100 and INH@MIL-100 NPs were efficiently internalized by A549 cells, mainly localized in the cytoplasm. In conclusion, the proposed micro-nanosystem is a good candidate for the pulmonary administration of anti-TB drugs.
Asunto(s)
Antituberculosos/farmacología , Isoniazida/farmacología , Estructuras Metalorgánicas/farmacología , Tuberculosis Pulmonar/tratamiento farmacológico , Células A549 , Administración por Inhalación , Antituberculosos/administración & dosificación , Antituberculosos/química , Cápsulas/administración & dosificación , Cápsulas/química , Cápsulas/farmacología , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Isoniazida/administración & dosificación , Isoniazida/química , Estructuras Metalorgánicas/administración & dosificación , Estructuras Metalorgánicas/química , Tamaño de la PartículaAsunto(s)
Antituberculosos/administración & dosificación , COVID-19/complicaciones , Neumotórax , Toracocentesis/métodos , Tuberculosis Miliar , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/fisiopatología , Niño , Humanos , India , Masculino , Neumotórax/diagnóstico por imagen , Neumotórax/etiología , Neumotórax/fisiopatología , Neumotórax/terapia , Radiografía Torácica/métodos , Respiración Artificial/métodos , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/terapia , SARS-CoV-2/aislamiento & purificación , Resultado del Tratamiento , Tuberculosis Miliar/complicaciones , Tuberculosis Miliar/diagnóstico , Tuberculosis Miliar/fisiopatología , Tuberculosis Miliar/terapia , Síndrome Post Agudo de COVID-19RESUMEN
A 30-year-old, multiparous widow, with postpolio residual paralysis, presented with complaints of dull aching abdominal pain for 15 days. Ultrasound showed a mixed echogenic right adnexal mass with free fluid in the pelvis and abdomen. CT abdomen and pelvis revealed partially defined peripherally enhancing collection in lower abdomen and right adnexa suggestive of tubo-ovarian abscess. There was mild ileal wall thickening and few enlarged mesenteric lymph nodes. Ascitic fluid did not show acid fast bacilli and cultures were sterile. Extensive diagnostic laboratory work was done which was inconclusive. Diagnostic laparoscopy could not be performed due to non-availability of elective operation theatre in the COVID-19 pandemic. Presumptive extrapulmonary tuberculosis was clinically and radiologically diagnosed. She was started on daily anti tuberculosis treatment. This case shows us the importance of imaging as a diagnostic tool and as an alternative for laparoscopy in COVID-19 pandemic to diagnose abdomino-pelvic tuberculosis.